Open AccessNarrative review on clinical considerations for patients with diabetes and COVID‐19: More questions than answers
Author(s) -
Katsiki Niki,
GómezHuelgas Ricardo,
Mikhailidis Dimitri P.,
PérezMartínez Pablo
Publication year - 2021
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.14833
Subject(s) - medicine , diabetes mellitus , observational study , type 2 diabetes , epidemiology , covid-19 , intensive care medicine , pandemic , telemedicine , diabetes management , disease , dipeptidyl peptidase 4 , disease management , randomized controlled trial , clinical trial , health care , endocrinology , infectious disease (medical specialty) , economic growth , parkinson's disease , economics
Background‐Aim Diabetes, obesity and hypertension are common comorbidities associated with increased severity and mortality rates from Corona Virus Disease (COVID)‐19. Methods In this narrative review (using the PubMed database), we discuss epidemiological data and pathophysiological links between diabetes and COVID‐19. The potential effects of glycaemic control and antidiabetic drugs on the prevalence and outcomes of COVID‐19 are also reviewed, as well as the role of telemedicine and diabetes self‐management in the post‐COVID‐19 era. Results Diabetes has been linked to COVID‐19 morbidity and mortality, although further research is needed to elucidate this association. In the meantime, physicians should be aware of the potential rise in the prevalence of diabetes (due to unhealthy lifestyle changes during the pandemic), its severity and complications and focus on achieving optimal diabetes prevention and management. Telemedicine and diabetes self‐management may help towards this direction. Dipeptidyl‐peptidase 4 (DPP4) inhibitors, glucagon‐like peptide‐1 (GLP‐1) receptor agonists and sodium‐glucose transporter 2 (SGLT2) inhibitors may affect viral entry and infection, and thus COVID‐19 outcomes, as shown in observational studies. Conclusion Diabetes has been associated with COVID‐19 development and progression. Certain antidiabetic drugs may influence COVID‐19 prevention and management. The results of ongoing randomized clinical trials will shed more light on this field.